Head-to-head evidence
Apomorphine (Apokyn) vs LY03003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine (Apokyn)
Marketed by Supernus Pharmaceuticals
NCT00142545 · Phase 3 · completed
The study was non-randomized, open-label, and had no comparator arm; all 800 participants received apomorphine. Its primary outcomes focused on safety monitoring, and no primary endpoint results were posted, so there is no controlled comparison showing benefit.
Next expected readout: December 2027 · NCT04957095 (registry estimate)
LY03003
Developed by Luye Pharma Group
NCT04571164 · Phase 3 · completed
The trial randomized 294 participants to LY03003 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical UPDRS parts II+III score over 24 weeks, but the primary comparison and safety findings are not available, preventing assessment of whether the endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Apokyn)'s landscape · LY03003's landscape